Caffeine Citrate Injection, USP and Caffeine Citrate Oral Solution, USP are indicated for the short-term treatment of apnea of prematurity in infants between 28 and less than 33 weeks gestational age.
Caffeine features the company’s PreventIV Measures packaging and labeling, designed to help reduce medication errors, according to Sagent.
The US market for Caffeine Citrate Injection, USP and Caffeine Citrate Oral Solution, USP was approximately $28.5m for the 12 months ending July 2012, according to IMS.